MABioN Webinar – Too Shy to Ask the Listserv: Biosafety Modernization Edition – 10/15/25
FREE Webinar – Wednesday, Oct 15, 2025 12pm CDT, 1pm EDT
It’s never been more important for biosafety professionals and institutions to submit questions! This webinar will begin with a brief presentation explaining the process. It will also encourage all shareholders to prepare to submit comments to the NIH to amplify the voices of biosafety in this process. This will be an interactive, open forum discussion without a formal panel. Participants can submit questions anonymously with their registration or live during the webinar.
NIH Amends NIH Guidelines to Modernize Gene Therapy Oversight and Establishes a Forum for Emerging Biotechnology (News from NIH-OSP)
Today, the National Institutes of Health (NIH) finalized a proposal to amend the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules(NIH Guidelines) to streamline the oversight of gene therapy research.
Registration Now Open for Upcoming OSP Workshop | NIH Guidelines: Honoring the Past, Charting the Future | July 18-19, 2017
In honor of the recent 40th anniversary of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) as well as the emergence of new technologies in the life sciences, it is an opportune time to examine the current biosafety oversight framework, and discuss the future direction of biosafety oversight. In the decades since scientists gathered at Asilomar, there has been considerable evolution in molecular biology, our understanding of risk and safety, and biosafety oversight. While recombinant DNA has become ubiquitous, new emerging technologies – ranging from new genome editing tools to novel RNA applications – are presenting interesting challenges to our current biosafety framework.
